Exacerbation of lymphomatoid papulosis during rituximab therapy

Australas J Dermatol. 2014 Feb;55(1):e1-3. doi: 10.1111/ajd.12002. Epub 2012 Nov 29.

Abstract

We report two cases of lymphomatoid papulosis (LyP) occurring in conjunction with B-cell lymphoproliferative malignancies where the LyP was exacerbated during rituximab (anti-CD20 antibody)-based therapy. We postulate that the altered B-cell cytokine milieu acted to allow an exacerbation of the patient's concomitant T-cell disease and discuss the possible mechanisms by which this may have occurred.

Keywords: CD30+ T-cell lymphoma; LyP; adverse effect; anti-CD20 antibody; lymphomatoid papulosis; rituximab.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / administration & dosage
  • Disease Progression*
  • Doxorubicin / administration & dosage
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / adverse effects*
  • Leukemia, Lymphocytic, Chronic, B-Cell / complications
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Lymphoma, Follicular / complications
  • Lymphoma, Follicular / drug therapy*
  • Lymphomatoid Papulosis / chemically induced
  • Lymphomatoid Papulosis / complications
  • Lymphomatoid Papulosis / immunology*
  • Male
  • Middle Aged
  • Prednisolone / administration & dosage
  • Rituximab
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives
  • Vincristine / administration & dosage

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisolone
  • Vidarabine
  • fludarabine